Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

GLP-1 After Heart Transplant: Study

A 14-center retrospective study found improved metabolic markers in selected heart transplant recipients, without proving comparative benefit or graft safety.

Why we wrote this. Transplant recipients are often excluded from trials. This readout describes the useful real-world signal without treating an uncontrolled cohort as proof of benefit or safety.

In this article (5 sections)
  1. The cohort was clinically specific
  2. Weight and glycemic markers improved over one year
  3. Tacrolimus levels changed modestly
  4. Recorded gastrointestinal tolerability was generally manageable
  5. What this study can and cannot support

A 2026 retrospective multicenter study followed heart transplant recipients with type 2 diabetes who received a GLP-1 receptor agonist. After one year, weight, glucose measures and several cardiometabolic markers improved on average. Gastrointestinal adverse events occurred in 12.0%, and 3.7% discontinued treatment because of them[1]. Without an untreated or active-comparator group, the study cannot show that the medicines alone caused the changes.

This was not a randomized trial. Researchers reviewed care delivered from 2011 through 2021 and assessed the first year after GLP-1 treatment began. That design can describe treatment use, laboratory changes and recorded tolerability in a population often missing from trials. It is less able to establish comparative benefit or detect every adverse event.

The cohort was clinically specific

The 108 treated recipients had a mean age of 55.4 years, and 79.6% were male. Treatment began an average of 4.0 years after heart transplantation. At baseline, 64.8% had obesity[2]. These features define the observed group and limit transfer to newly transplanted patients, people without type 2 diabetes or recipients of other organs.

Semaglutide accounted for 59% of use, dulaglutide for 27% and liraglutide for 13%. Tirzepatide accounted for only 1%[1]. The results are therefore mainly a GLP-1 receptor agonist class description, heavily influenced by semaglutide. They should not be presented as a meaningful test of tirzepatide.

Only 41.7% reached what the authors called the maximum therapeutic dose. The abstract does not explain each reason for stopping escalation. Tolerability, clinician preference, glycemic response and interactions with a complex transplant regimen may all influence treatment intensity. The study does not supply a dosing rule for transplant recipients.

Weight and glycemic markers improved over one year

Mean body weight fell by 6.2 kg, with a 95% confidence interval from minus 7.7 to minus 4.5 kg. Fasting glucose fell by 27 mg/dL, with an interval from minus 41 to minus 7, and HbA1c fell by 0.74 percentage points, with an interval from minus 1.12 to minus 0.35[2]. These are before-and-after changes among treated patients, not treatment effects versus a control.

A before-and-after comparison is vulnerable to several alternative explanations. Background diabetes treatment may change during follow-up. Diet, rehabilitation, adherence and regression toward the mean can also influence measurements. Patients who remain in follow-up may differ from those with missing data or early discontinuation.

Total cholesterol fell by 12 mg/dL, LDL cholesterol by 8 mg/dL and triglycerides by 29 mg/dL. Systolic blood pressure fell by 3.6 mm Hg[1]. These marker changes can be clinically relevant, but the study did not establish fewer cardiovascular events, graft failures or deaths. Surrogate outcomes and patient-important outcomes should remain separate.

Tacrolimus levels changed modestly

Tacrolimus trough concentrations decreased by 0.7 ng/mL on average. The 95% confidence interval ranged from minus 1.4 to minus 0.1 ng/mL, and the p value was 0.025. No episodes of acute rejection were recorded during the reported follow-up[2]. The absence of recorded rejection in 108 treated patients does not prove that an interaction is impossible or that monitoring can be relaxed.

Tacrolimus exposure matters because transplant recipients depend on stable immunosuppression. A trough-level change can reflect absorption, adherence, dose adjustment, timing of the blood draw or other medicines. The abstract does not provide a control group, detailed variability or an analysis showing what produced the change. Transplant teams, not a general study summary, must interpret levels for an individual.

The paper also cannot settle whether delayed gastric emptying meaningfully changes every immunosuppressant regimen. Different agents have different pharmacology and monitoring requirements. A class-level metabolic result should not be turned into an assumption about one patient's antirejection medicines.

Recorded gastrointestinal tolerability was generally manageable

Gastrointestinal adverse events were recorded in 12.0% of recipients, and 3.7% discontinued because of them[1]. Those figures describe this retrospective cohort. Medical records may miss mild symptoms, while clinicians may select patients thought more likely to tolerate treatment. There was no comparator group to show whether the rates differed from routine diabetes care after transplantation.

For broader context, the semaglutide safety section summarizes established clinical adverse effects. It cannot replace transplant-specific review, because immunosuppression, renal function, infection risk and nutritional status can change the consequences of vomiting, reduced intake or dehydration.

What this study can and cannot support

The study supports a cautious conclusion: GLP-1 receptor agonist treatment was feasible in selected heart transplant recipients with type 2 diabetes across 14 centers, and average metabolic markers improved during the following year. It does not establish superiority over another diabetes medicine, prove cardiovascular protection after transplant or demonstrate long-term graft safety.

A stronger next step would include a well-matched comparison group, predefined immunosuppressant monitoring and systematic adverse-event collection. Larger samples would be needed for uncommon outcomes such as rejection. Randomization would improve causal inference, though a carefully designed prospective registry could also address missing clinical details.

Heart transplant recipients should not start, stop or change a diabetes medicine based on this report alone. Decisions require coordination between transplant and diabetes clinicians, with individualized review of immunosuppression, hydration, nutrition and laboratory monitoring.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Was this a randomized trial in heart transplant recipients?

No. It was a retrospective multicenter study of 108 treated recipients from 14 Spanish centers, with no untreated or active-comparator group.

Which medicines did the recipients use?

Semaglutide accounted for 59%, dulaglutide 27%, liraglutide 13% and tirzepatide 1%. The study therefore offers almost no tirzepatide-specific evidence.

Did GLP-1 treatment affect tacrolimus levels?

Mean tacrolimus trough levels decreased modestly by 0.7 ng/mL. No acute rejection was recorded, but the study cannot exclude interactions or replace individual monitoring.

What adverse events were reported?

Gastrointestinal events were recorded in 12.0% of recipients and led to discontinuation in 3.7%. Retrospective records may not capture every symptom.

Sources

  1. [1]Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study. 2026. PMID 42934184.Tier 1 · primary↩
  2. [2]NCBI PubMed EFetch record and abstract for PMID 42934184Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars